pre-update Archives

Publication

Prediction of Time-dependent CYP3A4 Drug-drug Interactions by Physiologically-based Pharmacokinetic Modeling: Impact of Inactivation Parameters and Enzyme Turnover

Predicting the magnitude of time-dependent metabolic drug-drug (mDDIs) interactions involving cytochrome P-450 3A4 (CYP3A4) from…

CertaraJune 14, 2011

Publication

Model-based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor

A model-based strategy was used to inform the early clinical development of anacetrapib, a novel…

CertaraJune 1, 2011

Publication

Systems Pharmacology: Bridging Systems Biology and (PK/PD)

Mechanistic PKPD models are now advocated not only by academic and industrial researchers, but also…

CertaraMay 11, 2011

Publication

Beyond Publication Bias

In drug development, clinical medicine, or health policy making, basing one's decisions on a selective…

CertaraMay 1, 2011

Publication

The Development of UGT1A1 and 1A6 in the Pediatric Liver

UDP-glucuronosyltransferases (UGTs) are critical for the metabolism and clearance of drugs, chemicals, and hormones. The…

CertaraMay 1, 2011

Publication

Towards a Better Prediction of Peak Concentration, Volume of Distribution, and Half-life After Oral Drug Administration in Man, Using Allometry

It is imperative that new drugs demonstrate adequate pharmacokinetic properties, allowing an optimal safety margin…

CertaraMay 1, 2011

Publication

Pharmacokinetics of Clofarabine in Patients with High-risk Inherited Metabolic Disorders Undergoing Brain-sparing Hematopoietic Cell Transplantation

Clofarabine, a newer purine analog with reduced central nervous system toxicity, may prove advantageous in…

CertaraMay 1, 2011

Publication

Estimating Toxicity-related Biological Pathway Altering Doses for High-throughput Chemical Risk Assessment

We describe a framework for estimating the human dose at which a chemical significantly alters…

CertaraApril 18, 2011

Publication

Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-experienced and CCR5 Antagonist-naive Patients

TBR-652 is a novel CCR5 antagonist with potent in vitro anti-HIV activity. The objective of…

CertaraApril 12, 2011

Publication

In Silico Prediction of Efavirenz and Rifampicin Drug-drug Interaction Considering Weight and CYP2B6 Phenotype

This study aimed to test whether a pharmacokinetic simulation model could extrapolate nonclinical drug data…

CertaraApril 1, 2011

pre-update

Prediction of Time-dependent CYP3A4 Drug-drug Interactions by Physiologically-based Pharmacokinetic Modeling: Impact of Inactivation Parameters and Enzyme Turnover

Model-based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor

Systems Pharmacology: Bridging Systems Biology and (PK/PD)

Beyond Publication Bias

The Development of UGT1A1 and 1A6 in the Pediatric Liver

Towards a Better Prediction of Peak Concentration, Volume of Distribution, and Half-life After Oral Drug Administration in Man, Using Allometry

Pharmacokinetics of Clofarabine in Patients with High-risk Inherited Metabolic Disorders Undergoing Brain-sparing Hematopoietic Cell Transplantation

Estimating Toxicity-related Biological Pathway Altering Doses for High-throughput Chemical Risk Assessment

Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-experienced and CCR5 Antagonist-naive Patients

In Silico Prediction of Efavirenz and Rifampicin Drug-drug Interaction Considering Weight and CYP2B6 Phenotype

Newsletter sign up

Quick links

Solutions

Contact